Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxil, Carboplatin and Bevacizumab in TNBC
NCT00608972Phase 2Completed
- Sponsor
- Rutgers University
- Start
- May 2008
- Primary completion
- Jul 2015
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Targeted Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, carboplatin, bevacizumab in breast cancer, sponsored by Rutgers University. Started May 2008; status: completed.
02
Drugs
pegylated liposomal doxorubicincarboplatinbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00608972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00608972.